Innovative solution disinfects air

Friday, 16 October, 2020

Innovative solution disinfects air

An innovative air disinfection stick-on filter that can be integrated into all kinds of HVAC systems and kill up to 99.9% viruses and bacteria has been launched by NCH Asia Pacific.

The Everbrite Filter is designed for use in enclosed, air-conditioned areas to limit the risk of infection from airborne droplets caused by coughing, sneezing and even talking. If a building’s HVAC system is not properly managed, expelled airborne droplets can stay aloft within an enclosed area then circulate indoors, potentially spreading airborne viruses such as SARS-CoV-2.

Despite many people taking precautions by wearing masks, risk remains because masks are not worn 24/7 — they can also be worn improperly or of poor quality. Asymptomatic people can transmit the virus through a cough or sneeze, or even by talking. Viral spread is exacerbated when a virus is circulating in the HVAC system.

Equipped with encapsulation technology for the controlled release of active antimicrobials, the Everbrite Filter has a germicidal effect within 1 min of use, killing pathogenic bacteria, antibiotic-resistant bacteria and moulds, and providing persistent disinfection for 90 days.

SGS testing of the product found a >99.99% reduction rate against FCV (feline calicivirus is recommended to be the surrogate virus to substitute SARS-CoV-2) and a reduction of up to 99.9% reduction of more than 100 viruses and bacteria, without risk to human health.

NCH is working to help business such as hotels, commercial buildings, department stores, public transport operations and schools create fresh, clean and sanitised environments for the long term.

Image credit: ©

Related News

Fish oil's role in stopping superbugs

Australian scientists have discovered that regular fish oil has the potential to break down...

PanKind initiative sets sights on early detection of pancreatic cancer

PanKind has launched the PanKind Early Detection Initiative in a move to strategically work with...

Promising results from Novavax Phase 3 vaccine trial

Novavax's COVID-19 vaccine demonstrated 100% protection against moderate and severe disease,...

  • All content Copyright © 2021 Westwick-Farrow Pty Ltd